ABSTRACT Insulin-like growth factor-I (IGF-I), a polypeptide growth factor found in milk, is hypothesized to play a functional role in the growth and development of neonates, particularly the gastrointestinal tract. Considerable evidence, based on direct tracer studies with 125 I-labeled IGF-I and measurements of circulating IGF-I concentrations in neonatal animals fed a range of IGF-I doses, indicates that the intestinal absorption of IGF-I and the possible effect on metabolism and somatic growth are negligible. However, studies in neonatal animals indicate that oral administration of pharmacological doses of IGF-I increases small intestinal mucosal growth, whereas oral IGF-I provided within the physiological range may enhance the development of intestinal lactase. Therefore, clinical trials exploring the therapeutic use of oral IGF-I as an intervention for preterm neonates and those with compromised intestinal function seem warranted. However, milk-borne IGF-I may not be essential for normal healthy infants, perhaps because endogenous IGF-I provides a sufficient stimulus for maintenance of gastrointestinal structure and function. Future studies should explore the significance of endogenous IGF-I and whether milkborne IGF-I may be important under pathological conditions in which the endogenous IGF-I production may be compromised. J. Nutr. 127: 975S-979S, 1997.
There has been considerable interest in the function of role in the growth and development of neonates, but identimilk-borne growth factors since Klagsburn's original finding fying the functional significance has met with limited success. (1978) that human milk stimulates the proliferation of cul-
The original studies of Widdowson (Widdowson and Crabb tured fibroblasts. This observation has led to a concerted effort 1976, Widdowson et al. 1976 ) demonstrated the rapid growth to isolate and characterize the mitogenic factors present in of various organs and tissues of suckling neonatal pigs during milk. In the last 15-20 y, numerous polypeptide growth factors the first 10 d after birth. Subsequent studies have focused on have been found in milk, including insulin-like growth factorthe growth of the gastrointestinal tract, because this is the first I (IGF-I) (see reviews Grosvenor et al. 1992 , Zumkeller 1992 .
tissue exposed to ingested milk-borne growth factors (Berseth Additional studies have found that both the growth factor et al. 1983 ). Moreover, because many animal species, and content and mitogenic activity in colostrum are high, but perhaps preterm human infants, have an enhanced intestinal that they decrease considerably during the course of lactation permeability to macromolecules, in part related to the absorp- (Donovan et al. 1994 , Read et al. 1984 .
tion of colostral immunoglobulins during the early neonatal As this area of research has evolved, it has been repeatedly period, it has been argued that ingested milk-borne growth hypothesized that milk-borne growth factors have a functional factors may be absorbed into the blood and thus could conceivably affect the growth and metabolism of peripheral organs. This review will focus on the most recent findings and discuss 
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SUPPLEMENT II are severalfold higher in colostrum than in mature milk and groups have demonstrated that intestinal growth is particularly responsive to parenteral administration of relatively pharmacothat the levels decreased precipitously in the first few days of lactation. An additional truncated form of IGF-I (des-IGF-I) logical doses of IGF-I and its related analogs in normal weaned rats (Steeb et al. 1994 ) and after intestinal resection (Lemmey that was originally isolated from bovine colostrum lacks the N-terminal tripeptide (Gly-Pro-Glu), has reduced affinity for et al. 1991), dexamethasone treatment , total parenteral nutrition (Yang et al. 1994 ) and intestinal the IGF-binding proteins (IGFBP) and hence exhibits 10-to 100-fold greater biological activity than the normal full-length transplantation (Zhang et al. 1995) . These and other studies indicate that parenteral IGF-I increases both crypt cell proliferpeptide in in vitro bioassays (Francis et al. 1986) . A consideration that is particularly relevant, given that preterm human ation (Potten et al. 1995) and protein synthesis (Lo et al. 1996) and is associated with increased mucosal thickness and neonates frequently receive formula rather than breast milk, is that IGF-I has not been detected in infant formulas, presumintestinal length. Despite the convincing evidence that parenteral IGF-I stimulates intestinal growth, until recently few ably because it is either destroyed or removed during processing (Nagashima et al. 1990) .
studies have examined the potentially anabolic effect of orally or enterally administered IGF-I. Although intraluminal infuThe IGFBP also have been identified in human (Baxter et al. 1984) , porcine (Donovan et al. 1994 , Simmen et al. 1988 , sion of IGF-I has been shown to increase mucosal growth in rats (Olanrewaju et al. 1992) , more recent studies with both bovine (Skaar et al. 1991) and rodent (Donovan et al. 1991) milk. Four (BP-1, BP-2, BP-3, BP-4) of the six known IGFBP neonatal pigs (Houle et al. 1996 , Xu et al. 1994 ) and calves have shown that oral administration have been found in milk, including the 150-kDa IGFBP-3 complex, which contains the IGF-I peptide and the 85-kDa of physiological concentrations of IGF-I in formula results in measurable increases in crypt cell proliferation but no demonacid-labile subunit. In pigs, total IGFBP binding activity peaks on d 4 of lactation and then declines (Donovan et al. 1994) .
strable increase in intestinal mucosal mass or length. Thus, in contrast to studies in weaned rats showing a marked anabolic Despite the presence of these IGFBP in milk, there is little evidence to indicate whether these IGFBP either serve to effect of parenteral IGF-I, recent studies in neonatal animals suggest that oral administration of physiological doses of IGFprotect IGF-I from intestinal proteolytic activity or facilitate its binding to the enterocyte IGF-I receptor.
I has relatively modest effects on intestinal growth. These findings are consistent with our research on colostrum-fed neoIt is very important to recognize that in addition to the IGF-I ingested in milk or colostrum, the neonatal gastrointestinatal pigs (Burrin et al. 1995) , which suggests that the predominant factor affecting gastrointestinal protein synthesis is nutrinal tract is also exposed to endogenous IGF-I secreted in saliva (Costigan et al. 1988) , biliary fluid (Kong et al. 1995) and ent intake, and only a modest stimulation of intestinal protein synthesis can be attributed to non-nutritive components, pancreatic juice (Chaurasia et al. 1994) . Furthermore, the IGF-I concentrations present in gastrointestinal secretions are eiwhich include IGF-I. In addition to the possible physiological importance of either similar to or greater than that reported in milk and thus may be quantitatively and functionally significant. Analysis of ther colostral or milk-borne IGF-I, however, there also is growing interest in the therapeutic use of recombinant IGF-I to fetal and adult tissues has shown that both the IGF-I mRNA and peptide are expressed in all regions of the gastrointestinal enhance intestinal growth and maturation in preterm infants and neonates with loss of intestinal function as a result of tract, although they seem to be localized to the mesenchymal cells in the submucosa and lamina propria of the stomach and resection, total parenteral nutrition or diarrhea. To establish the therapeutic potential of orally administered IGF-I, we insmall intestine (Lund et al. 1986 ). This observation, coupled with the finding that the abundance of the IGF-I receptor is vestigated whether oral administration of recombinant human IGF-I (rhIGF-I) in formula would induce intestinal growth in greater in the crypt vs. villus enterocytes, suggests that IGF-I may exert a local paracrine growth stimulus for mucosal cell neonatal pigs at a dose comparable to that which induces intestinal growth in weaned rats when given parenterally (Burproliferation (Laburthe et al. 1988 ). However, IGF-I receptors are also present in other cell types within the intestinal murin et al. 1996b). The daily oral dose of rhIGF-I we used (3.5 mg/kg body wt) is severalfold greater than the maximum cosa, suggesting that circulating IGF-I also may affect intestinal mucosal growth.
amount of IGF-I normally ingested daily by neonatal pigs consuming either colostrum (Ç100 mg/kg body wt) or mature milk The IGFBP are also expressed in gastrointestinal tissues, but their cellular localization and the regulation of their ex-(Ç5 mg/kg body wt). This pharmacological dose of rhIGF-I pression are poorly understood, especially in neonates (see increased small intestinal mucosal growth and was associated review Zumkeller 1992) . Some evidence suggests that IGFBPwith increased mucosal thickness secondary to a lengthening 3 is localized in the lamina propria (Winesett et al. 1995) , of the villus rather than an increase in crypt depth. whereas other data indicate that some intestinal IGFBP are
We also recently demonstrated the intestinal trophic effects altered by intestinal resection and differentiation. However, of orally administered IGF-I ingested naturally in suckling mice as is the case with milk-borne IGFBP, it remains unclear to (Burrin et al. 1996a) . Using a recently developed transgenic what extent IGFBP produced within the intestinal mucosa mouse model (Hadsell et al. 1996) , which exhibits targeted have any functional role in modulation of IGF-I action. Aloverexpression of des(1-3) human IGF-I in the mammary though the presence of IGF-I, the type I receptor and several gland, we tested whether increased concentrations of des(1-3) IGFBP has been demonstrated in various tissues of the gastrohuman IGF-I, when ingested naturally in mother's milk, would intestinal tract of neonates, their regulation by diet, endocrine result in differences in intestinal growth in suckling neonatal status or stage of development is largely unknown and remains offspring. This transgenic approach should be considered phara critical area for future research. macological, because measurements using a human-specific immunoassay indicate that the concentration of des(1-3) human
ANABOLIC EFFECTS OF INSULIN-LIKE GROWTH
IGF-I in milk collected from the IGF-I transgenic mice is ap-FACTOR-I ON GASTROINTESTINAL TISSUES proximately 50 mg/mL and is more than 1000-fold greater than IGF-I in wild-type mouse milk (approximately 10-50 ng/mL). In the last 10 y, as quantities of recombinant IGF-I sufficient for in vivo studies have become available, a number of research Consistent with our findings in pigs, measurements of small
intestinal weight, protein synthesis and villus height in 8-d-IGF-I increases lactase activity by altering any one of these critical cellular events during maturation of the enterocyte. old neonatal mice suckled on IGF-I transgenic dams were significantly greater than for mice suckling wild-type dams.
The finding that oral IGF-I may increase intestinal lactase activity at relatively physiological doses reveals a potentially The observations from these studies demonstrate that pharmacological doses of IGF-I, whether given parenterally or enimportant function of milk-borne IGF-I, and the possible mechanism for this phenomenon deserves more in-depth interally, stimulate intestinal growth. However, the characteristic effects on intestinal morphology seem to be dependent on vestigation in the future. the route of administration. Parenteral IGF-I stimulates crypt, lamina propria and villus cell growth. However, when IGF-I INTESTINAL ABSORPTION OF MILK-BORNE is given orally, the increase in mucosal thickness is confined INSULIN-LIKE GROWTH FACTOR-I to an increase in the villus height, perhaps because of limited infiltration of luminal IGF-I into the lower crypt region of the Another fundamental question regarding the possible funcmucosa. The cellular mechanism ordinarily ascribed to the tion of milk-borne IGF-I and whether IGF-I can be used theracell-proliferative response to IGF-I is its mitogenic effect as a peutically in infants is whether it survives luminal digestion progression factor during DNA synthesis or the S-phase of the and is absorbed into the peripheral circulation in a biologically cell cycle (Baserga and Rubin 1993) . Alternatively, however, it active form. Because neonates of many species are capable is plausible that IGF-I treatment increases enterocyte lifespan, of significant absorption of intact macromolecules during the because IGF-I has been shown to inhibit cellular apoptosis perinatal period, a function critical for acquisition of maternal (Harrington et al. 1994 ). An important area for future research immunoglobulins (Lecce et al. 1964) , there is a reasonable will be to establish to what extent the anabolic effects of local probability that ingested milk-borne IGF-I might also be ab-IGF-I are mediated through these two cellular mechanisms, sorbed intact. An additional characteristic of the gastrointestiunder both pharmacological and normal physiological condinal tract of neonates that may enhance the survival of milktions.
borne IGF-I is the relatively low level of gastric acidity and luminal proteolytic digestion (Britton and Koldovsky 1989) .
Despite numerous reports that have characterized the ex-EFFECT OF INSULIN-LIKE GROWTH FACTOR-I
tent of luminal digestion and intestinal absorption of several ON INTESTINAL DEVELOPMENT milk-borne peptides, remarkably few such studies focus on IGF-AND MATURATION I (Britton and Koldovsky 1989) . Studies in vitro suggest that as little as 20% of 125 I-labeled IGF-I is degraded when it is In contrast to the number of reports describing the effects incubated with intestinal luminal contents from neonatal rats of IGF-I on intestinal growth, few studies have characterized and that coincubation with formula significantly decreases its effect on intestinal development and maturation. During IGF-I degradation (Rao et al. 1993) . The protective action of the neonatal period there are numerous changes in intestinal milk protein on IGF-I degradation has been confirmed in more function, notably the appearance of lactase during the early recent in vitro studies demonstrating that nearly 40% of the neonatal period and its subsequent decline associated with intact 125 I-labeled IGF-I coincubated with casein survives even weaning. One of the earliest reports of the effect of IGF-I in when incubated with the intestinal lumen contents from adult neonatal rats demonstrated that both oral and intraperitoneal rats (Xian et al. 1995) . These in vitro studies, coupled with administration increased the specific activity of several intestithe evidence of intestinal growth effects in neonatal animals, nal brush-border enzymes, including lactase (Young et al.
suggest that some proportion of orally administered IGF-I may 1990). Consistent with this, recent studies in neonatal pigs well survive intestinal digestion. However, in vivo studies with have demonstrated that oral administration of IGF-I increases both neonatal rats (Phillips et al. 1995b ) and pigs (Donovan small intestinal lactase and decreases leucine aminopeptidase et al. 1997) indicate that, although as much as 30% of an activity and does so in a dose-dependent manner within a orally administered dose of 125 I-labeled IGF-I can be recovered range of physiological doses (Houle et al. 1996) . Results from in the intestinal mucosa, there is very limited absorption into this study also indicated that the effects of orally administered peripheral circulation. In our studies using transgenic mice, IGF-I on lactase activity were greater at 14 d than at 7 d of despite the ingestion of 1000-fold higher concentrations of age, and in effect, retarded the normal ontogenic decline in des(1-3) human IGF-I, no des(1-3) human IGF-I was detected lactase activity. In contrast to these studies with relatively in plasma of the pups suckled on transgenic dams (Burrin et physiological doses of IGF-I (Houle et al. 1996 , Young et al. 1996a . Furthermore, only one of the reported studies in al. 1990), our studies have not observed any effect of oral which IGF-I was given orally showed a statistically significant pharmacological doses of IGF-I on intestinal lactase activity increase in either the circulating IGF-I concentration or pein either neonatal pigs or mice (Burrin et al. 1996a and 1996b) .
ripheral organ growth compared with control groups (BaumThere are many possible mechanisms that might explain rucker et al. 1994 , Burrin et al. 1996b , Houle et al. 1996 , Xu the effect of an oral physiological dose of IGF-I on intestinal et al. 1994) ; the one exception is a recent study that used lactase. In suckling neonates, the maturation of the intestinal neonatal rats (Phillips et al. 1995a) . Taken together, the availenterocyte during its migration from the crypt to the tip of able evidence suggests that intestinal absorption of orally adthe villus involves the transcription of the lactase phlorizin ministered rhIGF-I, even when given in pharmacological hydrolase gene, followed by multiple steps of post-translation amounts, is of limited physiological significance in neonates. processing before the mature form of the enzyme is inserted into the brush border (Danielsen et al. 1984) . It has been suggested that the increased enterocyte migration rate associ-IMPLICATIONS FOR HUMAN NEONATES ated with weaning contributes to the decreased expression of mature lactase and its specific activity (Tsuboi et al. 1981) .
Because there are no reported clinical studies, it is impossible to predict the extent to which findings in neonatal animals Thus, if indeed oral IGF-I affects enterocyte half-life by altering either cell migration rate or apoptosis, this might influence are directly applicable to human infants. Nevertheless, the current evidence suggests that oral administration of pharmalactase expression. However, it is conceivable that milk-borne for the functional development of neonates in pathological
